Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by NewAmsterdam Pharma Company B.V. NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer August 14, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights August 07, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease July 25, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares June 09, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares June 06, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares June 06, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients June 05, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 June 03, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Present at Jefferies Healthcare Conference May 31, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 May 23, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights May 08, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia April 24, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors April 03, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update March 31, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference March 01, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference February 09, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors February 06, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy January 17, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer December 19, 2022 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease November 23, 2022 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire Tickers FLAC Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
